Jennison Associates LLC Krystal Biotech, Inc. Transaction History
Jennison Associates LLC
- $155 Billion
- Q2 2024
A detailed history of Jennison Associates LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Jennison Associates LLC holds 520,390 shares of KRYS stock, worth $93.3 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
520,390
Previous 670,735
22.41%
Holding current value
$93.3 Million
Previous $119 Million
19.92%
% of portfolio
0.06%
Previous 0.08%
Shares
7 transactions
Others Institutions Holding KRYS
# of Institutions
272Shares Held
24.9MCall Options Held
270KPut Options Held
172K-
Black Rock Inc. New York, NY3.95MShares$708 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.87MShares$514 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.43MShares$436 Million6.1% of portfolio
-
State Street Corp Boston, MA1.33MShares$239 Million0.01% of portfolio
-
Redmile Group, LLC San Francisco, CA1.02MShares$183 Million12.22% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.6B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...